Easy to store, the Oxford/AstraZeneca vaccine approved this week by the British regulator and became the first major COVID vaccine candidate to publish peer-reviewed efficacy results specially from phase III. The AstraZeneca / Oxford vaccine has the advantage of being inexpensive (around 3 Dollars per dose), It is the first vaccine whose efficacy results have been validated by a scientific journal.
Peter Openshaw (Professor of Experimental Medicine at Imperial College London) said: “The interim results of clinical trials are impressive, we can use vaccination to prevent Coronavirus. The Astrazeneca/Oxford vaccine dosage was chosen as one that gives acceptable side effects and a half-dose starter dose is great news.